- Home
- OMH vs BLRX Comparison
OMH vs BLRX Comparison
Compare OMH & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMH
- BLRX
- Stock Information
- Founded
- OMH 2015
- BLRX 2003
- Country
- OMH Singapore
- BLRX Israel
- Employees
- OMH N/A
- BLRX N/A
- Industry
- OMH Real Estate
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- OMH Finance
- BLRX Health Care
- Exchange
- OMH Nasdaq
- BLRX Nasdaq
- Market Cap
- OMH 13.6M
- BLRX 15.3M
- IPO Year
- OMH 2023
- BLRX 2011
- Fundamental
- Price
- OMH $1.52
- BLRX $4.45
- Analyst Decision
- OMH Hold
- BLRX Strong Buy
- Analyst Count
- OMH 1
- BLRX 2
- Target Price
- OMH N/A
- BLRX $19.00
- AVG Volume (30 Days)
- OMH 5.4M
- BLRX 2.1M
- Earning Date
- OMH 07-07-2025
- BLRX 08-14-2025
- Dividend Yield
- OMH N/A
- BLRX N/A
- EPS Growth
- OMH N/A
- BLRX N/A
- EPS
- OMH N/A
- BLRX N/A
- Revenue
- OMH $7,976,578.00
- BLRX $22,340,000.00
- Revenue This Year
- OMH $28.40
- BLRX N/A
- Revenue Next Year
- OMH $23.07
- BLRX N/A
- P/E Ratio
- OMH N/A
- BLRX N/A
- Revenue Growth
- OMH 117.53
- BLRX 91.68
- 52 Week Low
- OMH $0.59
- BLRX $2.30
- 52 Week High
- OMH $6.20
- BLRX $35.60
- Technical
- Relative Strength Index (RSI)
- OMH 46.11
- BLRX 50.17
- Support Level
- OMH $1.45
- BLRX $3.79
- Resistance Level
- OMH $1.59
- BLRX $4.62
- Average True Range (ATR)
- OMH 0.40
- BLRX 0.56
- MACD
- OMH 0.02
- BLRX -0.13
- Stochastic Oscillator
- OMH 35.76
- BLRX 21.79
About OMH Ohmyhome Limited
Ohmyhome Ltd is a data and technology-driven property technology company based in Singapore. Through its subsidiaries, it operates a one-stop-shop property platform that provides end-to-end property solutions and services for its customers, which comprises brokerage services and emerging and other services, such as home renovation and furnishing services, listing and research, mortgage referral, legal services, and insurance referral services. The company derives its revenues from two sources: revenue from brokerage services, property management services, and revenue from emerging and other services.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.